Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

Stopped early · Phase 2

Conditions studied: Follicular Lymphoma, Small Lymphocytic Lymphoma

In brief

This is a phase 2, open label study to assess umbralisib in combination with ublituximab in participants with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).

Key facts

Study ID

NCT03828448

Run by

TG Therapeutics, Inc.

People needed

34

Starts

2019-07-10

Expected to finish

2022-05-31

Last updated by the study team

2023-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of FL or SLL.
• Measurable disease that requires treatment
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

You may not qualify if…

• Currently or previously received treatment for their lymphoma
• Received wide field radiotherapy within 28 days or limited field radiation within 14 days of Cycle 1 Day 1
• Evidence of hepatitis B virus, hepatitis C virus or known human immunodeficiency virus (HIV) infection

Where it is running

• TG Therapeutics Investigational Trial Site — Fort Myers, Florida, United States
• TG Therapeutics Investigational Trial Site — St. Petersburg, Florida, United States
• TG Therapeutics Investigational Trial Site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.